Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-066421
Filing Date
2025-05-08
Accepted
2025-05-08 08:06:33
Documents
71
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q artv-20250331.htm   iXBRL 10-Q 2720499
2 EX-10.1 artv-ex10_1.htm EX-10.1 94446
3 EX-31.1 artv-ex31_1.htm EX-31.1 13190
4 EX-31.2 artv-ex31_2.htm EX-31.2 13210
5 EX-32.1 artv-ex32_1.htm EX-32.1 14027
6 GRAPHIC img261316817_0.jpg GRAPHIC 14099
  Complete submission text file 0000950170-25-066421.txt   10197432

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT artv-20250331.xsd EX-101.SCH 1299040
74 EXTRACTED XBRL INSTANCE DOCUMENT artv-20250331_htm.xml XML 1769402
Mailing Address 5505 MOREHOUSE DRIVE SAN DIEGO CA 92121
Business Address 5505 MOREHOUSE DRIVE SAN DIEGO CA 92121 (858) 267-4467
Artiva Biotherapeutics, Inc. (Filer) CIK: 0001817241 (see all company filings)

EIN.: 863614316 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42179 | Film No.: 25923989
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)